In vitro activity of the oxazolidinone RWJ-416457 against linezolid-resistant and -susceptible staphylococci and enterococci

David M. Livermore; Marina Warner; Shazad Mushtaq; Sarah North; Neil Woodford

doi:10.1128/AAC.01347-06

In vitro activity of the oxazolidinone RWJ-416457 against linezolid-resistant and -susceptible staphylococci and enterococci

David M. Livermore^*
, Marina Warner
, Shazad Mushtaq
, Sarah North
, Neil Woodford

^*Corresponding author for this work

RSD Divisional Office

Research output: Contribution to journal › Article › peer-review

38 Citations (Scopus)

Abstract

RWJ-416457, a novel oxazolidinone, had modal MICs of 0.5 to 1 μg/ml for linezolid-susceptible staphylococci and enterococci, versus linezolid MICs for these organisms of 1 or 2 μg/ml. RWJ-416457 MICs for mutants with 23S rRNA mutations were 2 to 32 μg/ml, versus linezolid MICs of 8 to 64 μg/ml; actual values reflected the proportion of gene copies mutated.

Original language	English
Pages (from-to)	1112-1114
Number of pages	3
Journal	Antimicrobial Agents and Chemotherapy
Volume	51
Issue number	3
DOIs	https://doi.org/10.1128/AAC.01347-06
Publication status	Published - Mar 2007

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1128/AAC.01347-06

Cite this

@article{fe55072e48ca43b0bbe4a7979b9e6461,

title = "In vitro activity of the oxazolidinone RWJ-416457 against linezolid-resistant and -susceptible staphylococci and enterococci",

abstract = "RWJ-416457, a novel oxazolidinone, had modal MICs of 0.5 to 1 μg/ml for linezolid-susceptible staphylococci and enterococci, versus linezolid MICs for these organisms of 1 or 2 μg/ml. RWJ-416457 MICs for mutants with 23S rRNA mutations were 2 to 32 μg/ml, versus linezolid MICs of 8 to 64 μg/ml; actual values reflected the proportion of gene copies mutated.",

author = "Livermore, \{David M.\} and Marina Warner and Shazad Mushtaq and Sarah North and Neil Woodford",

year = "2007",

month = mar,

doi = "10.1128/AAC.01347-06",

language = "English",

volume = "51",

pages = "1112--1114",

journal = "Antimicrobial Agents and Chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology",

number = "3",

}

TY - JOUR

T1 - In vitro activity of the oxazolidinone RWJ-416457 against linezolid-resistant and -susceptible staphylococci and enterococci

AU - Livermore, David M.

AU - Warner, Marina

AU - Mushtaq, Shazad

AU - North, Sarah

AU - Woodford, Neil

PY - 2007/3

Y1 - 2007/3

N2 - RWJ-416457, a novel oxazolidinone, had modal MICs of 0.5 to 1 μg/ml for linezolid-susceptible staphylococci and enterococci, versus linezolid MICs for these organisms of 1 or 2 μg/ml. RWJ-416457 MICs for mutants with 23S rRNA mutations were 2 to 32 μg/ml, versus linezolid MICs of 8 to 64 μg/ml; actual values reflected the proportion of gene copies mutated.

AB - RWJ-416457, a novel oxazolidinone, had modal MICs of 0.5 to 1 μg/ml for linezolid-susceptible staphylococci and enterococci, versus linezolid MICs for these organisms of 1 or 2 μg/ml. RWJ-416457 MICs for mutants with 23S rRNA mutations were 2 to 32 μg/ml, versus linezolid MICs of 8 to 64 μg/ml; actual values reflected the proportion of gene copies mutated.

UR - https://www.scopus.com/pages/publications/33847649581

U2 - 10.1128/AAC.01347-06

DO - 10.1128/AAC.01347-06

M3 - Article

C2 - 17210773

AN - SCOPUS:33847649581

SN - 0066-4804

VL - 51

SP - 1112

EP - 1114

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

IS - 3

ER -

In vitro activity of the oxazolidinone RWJ-416457 against linezolid-resistant and -susceptible staphylococci and enterococci

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this